The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms (2017)
- Authors:
- Fenerich, Bruna Alves
- Machado Neto, João Agostinho
- Alves, Ana Paula Nunes Rodrigues
- Campos, Paula de Melo - Universidade Estadual de Campinas (UNICAMP)
- Fernandes, Jaqueline Cristina
- Coelho-Silva, Juan Luiz
- Ribeiro, Renata Scopim
- Silva,Fernanda B. da
- Scheucher, Priscila Santos
- Figueiredo-Pontes, Lorena Lobo
- Rego, Eduardo Magalhães
- Traina, Fabiola
- USP affiliated authors: MACHADO NETO, JOÃO AGOSTINHO - ICB ; SCHEUCHER, PRISCILA SANTOS - FMRP ; REGO, EDUARDO MAGALHÃES - FMRP ; TRAINA, FABÍOLA - FMRP
- Unidades: ICB; FMRP
- Subjects: QUIMIOTERAPIA; NEOPLASIAS; DOENÇAS HEMATOLÓGICAS
- Language: Inglês
- Imprenta:
- Publisher place: Washington
- Date published: 2017
- Source:
- Conference titles: Annual meeting and Exposition of American Society of Hematology (ASH)
-
ABNT
FENERICH, Bruna Alves et al. The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: http://www.bloodjournal.org/content/130/Suppl_1/1253. Acesso em: 06 maio 2024. , 2017 -
APA
Fenerich, B. A., Machado Neto, J. A., Alves, A. P. N. R., Campos, P. de M., Fernandes, J. C., Coelho-Silva, J. L., et al. (2017). The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Recuperado de http://www.bloodjournal.org/content/130/Suppl_1/1253 -
NLM
Fenerich BA, Machado Neto JA, Alves APNR, Campos P de M, Fernandes JC, Coelho-Silva JL, Ribeiro RS, Silva FB da, Scheucher PS, Figueiredo-Pontes LL, Rego EM, Traina F. The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms [Internet]. Blood. 2017 ; 130[citado 2024 maio 06 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/1253 -
Vancouver
Fenerich BA, Machado Neto JA, Alves APNR, Campos P de M, Fernandes JC, Coelho-Silva JL, Ribeiro RS, Silva FB da, Scheucher PS, Figueiredo-Pontes LL, Rego EM, Traina F. The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms [Internet]. Blood. 2017 ; 130[citado 2024 maio 06 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/1253 - A inibição farmacológica de IRS1/2 induz apoptose em células BCR-ABL1 T315I
- IGF signaling predicts outcomes and is a promising target therapy for acute myeloid leukemia
- Stathmin 1 é altamente expressa em leucemia promielocítica aguda e a dinâmica dos microtúbulos é um alvo potencial para células PML-RAR resistentes ao atra
- A ativação da via IGF1R prediz prognóstico e representa uma estratégia terapêutica em leucemia mieloide aguda
- Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models
- Stathmin 1 is highly expressed in acute promyelocytic leukemia and microtubule dynamics is a potential target for ATRA-resistant APL cells
- Pharmacological IRS1/2 inhibition induces apoptosis in BCR-ABL1T315I mutant cells
- Reversine triggers mitotic catastrophe and apoptosis in BCR-ABL positive cells
- Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells
- Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
